The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 23, 2024
Filed:
Oct. 02, 2018
The Broad Institute, Inc., Cambridge, MA (US);
Massachusetts Institute of Technology, Cambridge, MA (US);
Dana-farber Cancer Institute, Inc., Boston, MA (US);
Aviv Regev, Cambridge, MA (US);
Orit Rozenblatt-Rosen, Cambridge, MA (US);
Benjamin Izar, Boston, MA (US);
Livnat Jerby, Cambridge, MA (US);
Asaf Rotem, Boston, MA (US);
The Broad Institute, Inc., Cambridge, MA (US);
Massachusetts Institute of Technology, Cambridge, MA (US);
Dana-Farber Cancer Institute, Inc., Boston, MA (US);
Abstract
The subject matter disclosed herein is generally directed to detecting and modulating novel gene signatures for the treatment and prognosis of cancer. The novel gene signatures predict overall survival in cancer and can be targeted therapeutically. Specifically, disclosed is a resistance program identified by a comprehensive single-cell profiling study in melanoma patients, which was validated in two large validation cohorts. Using a large-scale in silico prediction, CDK4/6 inhibitors were identified as a class of drugs that may reverse this resistance program. These predictions were validated in melanoma cell lines, patient-derived co-culture models, and melanoma in vivo models, which show that the combination of abemaciclib and immune checkpoint blockade (ICB) overcome intrinsic drug resistance. The present invention provides for detecting an immunotherapy resistance signature and modulating the signature with CDK4/6 inhibition. Also provided is a novel phased immunotherapy and CDK4/6 inhibitor combination therapy regimen.